Advancing Treatment of Disease with Innovative protein therapeutics and Technologies
Targeted treatment against anemia
TBI 304H is a humanized monoclonal antibody designed to target the CD163 receptor pathway on hematopoietic progenitor cells as a potential treatment of anemia. This receptor is involved in the development of red blood cells from hematopoietic progenitor cells.
The discovery of the CD163 receptor-mediated signaling pathway in hematopoietic progenitor cells represents an innovative mechanism to treat chronic anemia. This is one of several new candidates in an emerging field of potential treatments developed for anemia that use a novel signaling pathway that is independent of the erythropoietin pathway.
Further characterization of the CD163 signaling cascade may lead to the development of additional erythropoietin-independent targets in the field of anemia.
The US Food and Drug Administration (FDA) has given Therapure Innovations’ approval to proceed with a Phase 1 clinical trial, which is a single-center, open-label, intrasubject escalating dose study evaluating the safety, tolerability and pharmacokinetics of TBI 304H in patients experiencing chemotherapy-induced anemia.
TBI 304H Mechanism of Action Video
To view video, please click on image